Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FDD81
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $48,750
Award facts
- Contract value 100% obligated
- $48,749.85 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $48,749.85 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, represents a small individual purchase within a larger pharmaceutical supply relationship. The award carries no set-aside designation, demonstrating the contractor's ability to compete effectively in unrestricted federal procurement. Performance is scheduled to occur at the contractor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical sourcing for Department of Defense healthcare operations. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare facilities worldwide. DMS Pharmaceutical Group's established track record supplying diverse pharmaceutical products—ranging from oncology treatments to specialty biologics like Stelara—demonstrates its capability as a critical pharmaceutical supplier within the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FDD81?
SPE2DB26FDD81 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 27, 2025.
How much is contract SPE2DB26FDD81 worth?
The government has obligated $48,750 on SPE2DB26FDD81.
Is contract SPE2DB26FDD81 an order under another contract?
Yes. SPE2DB26FDD81 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB26FDD81 competed?
The extent of competition for SPE2DB26FDD81 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award